Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | ARAF | P10398 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11568049 | 0.89 | CYP19A1 (0.47) | SIGMAR1CYP19A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1655800 | 0.85 | ACHE (0.48) | ACHESIGMAR1CYP19A1RBP4TTR | |
| SCHEMBL13419646 | 0.85 | S1PR4 (0.50) | ACHESIGMAR1CYP19A1HPGDCHRNB4 | |
| SCHEMBL446992 | 0.84 | ACHE (0.51) | ACHESIGMAR1CYP19A1CYP1A2CYP2C19 | |
| SCHEMBL4929532 | 0.82 | MAPT (0.46) | ACHECYP19A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL21644446 | 0.82 | DRD4 (0.51) | ACHESIGMAR1CYP19A1CYP1A2CYP2C9 | |
| SCHEMBL4495673 | 0.82 | CYP19A1 (0.49) | ACHESIGMAR1CYP19A1CYP1A2CYP2C9 | |
| SCHEMBL2124399 | 0.82 | ACHE (0.49) | ACHESIGMAR1CYP19A1SIRT6HPGD | |
| SCHEMBL6230486 | 0.80 | ACHE (0.44) | ACHESIGMAR1CYP19A1CTSSRBP4 | |
| SCHEMBL4377013 | 0.80 | CYP19A1 (0.49) | ACHESIGMAR1CYP19A1CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105801584-B | Novel aryl amide Raf kinase and its preparation method and application | 中国药科大学 | 2019-03-05 | — | — | CN | disclosed |
| CN-105801584-A | Novel aromatic amide Raf kinase inhibitors and preparation method and application thereof | 中国药科大学 | 2016-07-27 | — | — | CN | disclosed |
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
| CN-101291917-A | Diaryl urea derivatives for the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2008-10-22 | — | — | CN | disclosed |
| EP-1689376-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051366-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | RET, PRKDC, PRKACA | ACHE 3851/4885SIGMAR1 4157/4885CYP19A1 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.